Puerarin, also known as 8-(β-D-Glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, is a plant isoflavonoid derivative derived from the dried roots of Pueraria lobata (Willd.) Ohwi, a leguminous plant. It possesses various pharmacological activities, including lowering blood pressure, blood lipids, and blood glucose, scavenging free radicals, and exhibiting antioxidant properties. This article provides a comprehensive pharmacological analysis of puerarin, examining its diverse effects on the human body.
We provide Puerarin Powder CAS 3681-99-0, please refer to the following website for detailed specifications and product information.
Chemical Properties and Extraction
Puerarin has a molecular weight of 416.37 and exists as a white needle-like crystal in methanol-acetic acid, with a melting point of 187°C (decomposition). The chemical structure of puerarin consists of a flavonoid backbone substituted with a β-D-glucopyranosyl moiety.
Puerarin is derived from the dried roots of Pueraria lobata, a plant traditionally used in Chinese medicine. To isolate puerarin, scientists employ a combination of solvent systems and purification techniques tailored to extract this compound effectively from the plant material. Typically, solvents such as methanol, ethanol, or combinations of these with acetic acid are used to dissolve and extract puerarin from the dried roots. Following extraction, the crude puerarin extract undergoes purification steps to remove impurities and ensure the purity of the final product. These purification techniques may include crystallization, chromatography, or other methods tailored to separate puerarin from other components in the extract.
|
|
|
Cardiovascular Effects
Puerarin exhibits several beneficial effects on the cardiovascular system, making it a valuable compound in the treatment of cardiovascular diseases.
Administering puerarin to rats via intraperitoneal or subcutaneous injection has been shown to counteract acute myocardial ischemia induced by pituitrin. In anesthetized dogs, intracoronary infusion of puerarin significantly increases coronary blood flow and decreases vascular resistance. Intravenous administration also increases blood flow in the internal carotid and femoral arteries, albeit less significantly than in the coronary arteries. The effect of puerarin on coronary circulation persists even after reserpine administration, suggesting a direct relaxing effect on vascular smooth muscle.
Puerarin attenuates the hypertensive or hypotensive responses to norepinephrine and acetylcholine in hypertensive animals. Intravenous injection of puerarin in hypertensive patients results in a decrease in blood pressure, heart rate, and plasma catecholamine levels, indicating a possible reduction in sympathetic nervous system activity. Additionally, puerarin opposes the excitatory effects of isoproterenol on isolated or in vivo hearts and reduces normal heart rate and blood pressure.
Puerarin at a dosage of 100 mg/kg can counteract chloroform-adrenaline-induced arrhythmia in rabbits. In guinea pigs poisoned with ouabain, puerarin significantly increases the ventricular ectopic (VE) and ventricular tachycardia (VT) thresholds but has a less pronounced effect on the ventricular fibrillation (VF) threshold. However, puerarin is less effective than propranolol and pronethalol in antagonizing arrhythmias induced by aconitine.
Intravenous puerarin administration significantly limits the extent of experimental acute myocardial infarction in dogs, confirmed by epicardial electrocardiography, enzymes, myocardial radionuclide scanning, and N-BT pathological staining. In anesthetized dogs, puerarin does not affect myocardial contractility but increases collateral blood flow during regional myocardial ischemia (and also increases coronary blood flow in non-ischemic areas) and reduces hemodynamic parameters related to myocardial oxygen consumption.
Topical infusion of 0.5% puerarin in mice antagonizes adrenaline-induced arterial constriction, decreased flow velocity, and reduced blood flow. Administering 1% puerarin after adrenaline-induced microcirculatory disturbances yields similar results. Intravenous puerarin at 52 mg/kg followed by adrenaline infusion attenuates adrenaline-induced microarterial constriction, decreased flow velocity, and reduced blood flow, outperforming papaverine. Puerarin also significantly improves normal hamster brain microcirculation and microcirculatory disturbances induced by topical norepinephrine by increasing microvascular motion amplitude and local microvascular blood flow.
Antioxidant and Anti-inflammatory Effects
Puerarin possesses potent antioxidant and anti-inflammatory activities, which contribute to its protective effects against various oxidative stress-related diseases.
Free Radical Scavenging
Puerarin acts as a free radical scavenger, protecting cells from oxidative damage. Studies have shown that puerarin can scavenge reactive oxygen species (ROS) and reduce oxidative stress, thereby protecting cellular structures and functions.
Protection Against Cadmium-induced Damage
Research has demonstrated that puerarin exhibits protective effects against cadmium (Cd)-induced damage in pakchoi (a type of Chinese cabbage). Co-treatment with puerarin and Cd significantly reduced oxidative damage, decreased hydrogen peroxide (H2O2) and malondialdehyde (MDA) contents, and increased chlorophyll, vitamin C (Vc), and soluble protein contents, as well as antioxidant enzyme activities. These findings suggest that an appropriate dose of puerarin can alleviate Cd-induced inhibition of aboveground growth in pakchoi and reduce Cd uptake.
Hypoglycemic Effect
Puerarin exhibits hypoglycemic activity, making it a potential therapeutic agent for diabetes mellitus.
Administering puerarin to alloxan-induced hyperglycemic mice at dosages of 250 and 500 mg/kg/day for 4-5 consecutive days significantly reduces blood glucose levels. The hypoglycemic effect of 500 mg/kg puerarin is more pronounced, with 250 mg/kg being close to the minimum effective dose. Additionally, a combination of puerarin and aspirin has a comparable hypoglycemic effect to high-dose puerarin alone, with the hypoglycemic effect lasting for over 24 hours and significantly improving glucose tolerance in alloxan-induced hyperglycemic mice.
Antiplatelet Aggregation
Puerarin inhibits platelet aggregation, which is crucial in preventing cardiovascular events such as thrombosis and myocardial infarction.
Inhibition of Platelet Aggregation
In vitro studies have shown that puerarin inhibits ADP-induced platelet aggregation in rats and the aggregation of rabbit, sheep, and human platelets induced by 5-hydroxytryptamine (5-HT) and ADP. Furthermore, puerarin significantly inhibits the release of ³H-5-HT from platelets induced by thrombin at certain concentrations.
Toxicity and Adverse Reactions
The median lethal dose (LD50) of puerarin in mice is 738 mg/kg when administered intravenously, indicating its relatively low toxicity. However, adverse reactions such as dizziness, headache, and nausea have been reported in some cases, particularly at high dosages or prolonged use. Therefore, it is crucial to monitor patients closely during puerarin therapy and adjust the dosage accordingly to minimize adverse effects.
Conclusion
Puerarin is a multifaceted compound with a wide range of pharmacological activities. Its cardiovascular effects, including coronary and cerebral vasodilation, antihypertensive properties, anti-arrhythmic activity, and beneficial effects on myocardial infarction and ischemia, make it a valuable therapeutic agent for cardiovascular diseases. Additionally, puerarin's antioxidant and anti-inflammatory activities protect cells from oxidative damage and inflammation, while its hypoglycemic and antiplatelet aggregation effects further broaden its therapeutic potential. Despite its relatively low toxicity, close monitoring of patients during puerarin therapy is essential to minimize adverse effects. Future research should focus on elucidating the underlying mechanisms of puerarin's pharmacological activities and exploring its potential in the treatment of other diseases.